No significant benefit of Umifenovir in COVID-19 treatment: Glenmark

No significant benefit of Umifenovir in COVID-19 treatment: Glenmark New Delhi, Oct 9 : Drug firm Glenmark Pharmaceuticals on Friday said the addition of antiviral Umifenovir did not demonstrate any significant clinical benefit over Favipiravir alone in moderate COVID-19 patients. https://ift.tt/eA8V8J